Ultra Market Research | United States(U.S.) Genomics Market
United States(U.S.) Genomics Market
Report ID : 621
Category : Biotechnology,United-States(US)
No Of Pages : 140
Published on: August 2024
Status: Published
Format :
Key Question Answer
Global Market Outlook
In-depth analysis of global and regional trends
Analyze and identify the major players in the market, their market share, key developments, etc.
To understand the capability of the major players based on products offered, financials, and strategies.
Identify disrupting products, companies, and trends.
To identify opportunities in the market.
Analyze the regional penetration of players, products, and services in the market.
Comparison of major players financial performance.
Evaluate strategies adopted by major players.
Recommendations
United States (U.S.) Genomics Market Estimated at US$ XX billion in 2023, the U.S. genomics industry is projected to reach around US$ XX billion by 2033, with a compound annual growth rate (CAGR) of XX% from 2024 to 2033. The study of a person's complete genetic composition and how it interacts with other genes and the environment is known as genomics, and it is thriving in the large and varied healthcare system in the United States. The nation is well-known in this subject because to renowned research facilities, a large number of noteworthy genomics projects, and prominent individuals. In addition, the considerable and well-established healthcare sector in the United States keeps developing due to the country's increasing population. The expansion of healthcare and genomic advancements are mutually reinforcing, which drives the growth trajectory of the U.S. genomics market.
Market Overview Growing understanding of an organism's entire genome and its interactions with its surroundings is driving the rapid rise of the U.S. genomics sector. States that require genetic screening for newborns—of which 95% of them do—highlight the importance of this industry. However, because newborn screening is governed at the state level, testing criteria differ by location. The Human Genome Project (HGP), an endeavor spearheaded by the US government and which resulted in the first full sequencing of a human genome in 2000, was completed, marking a significant turning point in the field of genomics. Thanks to developments, it is now possible to sequence a person's entire genome in less than 24 hours for a reasonable price, giving customers access to DNA sequences that show their ethnic heritage. Beyond the field of medicine, genomics finds use in anthropology, biotechnology, agriculture, and other social sciences. This broad range of applications contributes to the field's explosive expansion and diverse effects on a variety of businesses.
Report Highlights By Application & Technology Market is dominated by the functional genomics segment, which is driven by improvements in drug discovery made possible by functional genomics techniques. By identifying possible therapeutic targets, this method makes it easier to investigate the impact of genes and how they relate to illnesses. Of all the tools out there, CRISPR/Cas9 is the most potent and adaptable gene editing instrument. By analyzing gene function and regulation within dynamic systems using genomic and omic data, functional genomics provides important new understandings into the effects of genetic variants on health and disease. Functional genomics with CRISPR/Cas9 technology spurs innovation in drug discovery and treatment development, driving market growth with its capacity to clarify biological processes at the molecular level. With genomics expected to increase at a significant rate in the near future, pathway analysis appears to be a leader in this regard. The availability of next-generation sequencing is expanding, which makes it a good time to review approaches for pathway-based analysis of genomic data. Pathway analysis techniques are essential to life sciences research because they use statistical tests and algorithms along with biomolecular understanding to extract biological relevance from high-throughput biological data. Even with their extensive use, the fundamentals of pathway analysis require ongoing improvement in order to stay up with the rapidly changing needs of data analysis and genomic research.
By Deliverable With the highest stake in the US genomics market, the goods segment continues to cement its dominance. This category includes a wide range of items, including plastic products, PCR reagents, real-time PCR systems, heat cyclers, NGS library prep kits, ddPCR, and ddSEQ Systems. Notably, the product lines offer a wide variety of reagents specifically designed for PCR, real-time PCR, and reverse transcription that have been painstakingly refined to produce reliable and precise results. Furthermore, the section plays a crucial role in enabling genomic research and applications because experimentally verified PCR primer and probe assays support a variety of investigations, such as copy number variation, gene expression, and mutation detection. In the U.S. genomics market, services are expected to increase at the second-fastest rate behind goods, which continue to lead the market. Whole genome sequencing, whole exome sequencing, targeted panel sequencing, shotgun metagenomics, and 16S rRNA gene sequencing are just a few of the services that fall under this category. Notably, the Genomics Services Laboratory (GSL) has more than ten years of experience in the creation and interpretation of next-generation sequencing (NGS) data. GSL provides all-inclusive assistance for NGS, including library preparation, sequence production, data analysis, and experimental design. GSL is a major provider of genomics services in the industry because it effectively analyzes complicated sequencing datasets, including integrated DNA and RNA sequence data, by utilizing advanced bioinformatics skills.
By End-Use With the biggest market share in the US genomics market, pharmaceutical and biotechnology businesses are the main end customers. Because it allows firms to design safer, more effective therapies that target the underlying disease directly rather than just its symptoms, genomics plays a critical role in modernizing the drug development process. Genomics enables the discovery of potential repurposing opportunities for existing medications that have been shown to be safe in people and approved for use in various settings by identifying the underlying causes of diseases within a genomic framework. This deliberate use of genetics into medication development procedures highlights how important it is to enhance overall patient outcomes and spur innovation in the biotechnology and pharmaceutical industries. The clinical research industry in the United States is poised for substantial expansion. By utilizing genomes, clinical researchers can obtain very efficient diagnostic probes that can identify hereditary features and frequently prevent symptoms from arising. Recent developments in genomics provide new approaches to the diagnosis of diseases at the DNA, RNA, and bioactive protein levels, enabling more thorough disease detection. Furthermore, technologies similar to those used in the production of microcircuits can be used to mechanize genomic approaches, allowing for the simultaneous screening of thousands of disorders utilizing microarrays. In addition to improving disease diagnosis, this thoughtful incorporation of genetics into clinical research spurs innovation and advances the industry's growth trajectory.
Market Dynamics Driver Genomic Medicine Revolutionizes Healthcare Combination of genomics and DNA sequencing in medicine provides a wealth of information about the molecular biology of individuals, revealing genetic variations and mutations that guide individualized treatment regimens. This move away from a one-size-fits-all strategy and toward customized care based on each patient's unique genetic makeup has enormous potential for use in all phases of healthcare, including diagnosis, treatment, and prevention. With the ability to diagnose conditions more quickly and accurately and provide patients with individualized treatment for genetic diseases and cancer, genomic medicine has become increasingly popular in a number of fields, including prenatal care, cancer, pharmacology, uncommon diseases, and infectious diseases. Healthcare progress is further propelled by the acceptance of precision medicine and the use of genomes to optimize drug administration. It is anticipated that these developments would open the door for new technologies, such as cancer vaccine centers and related studies, which will spur expansion in the US genomics sector.
Restraints Complex Ethical, Legal, and Social Implications With the introduction of genomics come a plethora of complex legal, social, ethical, and economic issues, in addition to worries about potential risks and hazards. Concerns about privacy violations, social stigma, and possible exploitation of genetic data are relevant, especially in light of the possibility of creating a genetic underclass that could be denied health insurance due to results of genetic testing. Concerns are heightened by issues with DNA sequence intellectual property rights and the use of populations in developing nations for genetic databases, frequently at the request of businesses in the rich world. The lack of strong international intellectual property laws widens the divide between industrialized and developing nations, which limits the possibility for growth in the U.S. genomics market.
Opportunities Advancements in Genomics Even though genomics is complicated and it can be difficult to foresee its full health effects since gene products interact in complex ways, poor nations have a lot of potential to concentrate on taking immediate steps to improve public health and healthcare systems. The human genome sequencing project, in conjunction with the continuing and projected advancements in genomics, offers a once-in-a-lifetime chance to improve our comprehension of the role that genetics plays in human health and disease. This new understanding makes it possible to distinguish non-genetic impacts more precisely and speeds up the application process for illness prevention, diagnosis, and therapy. These developments put the U.S. genomics market at the forefront of revolutionary healthcare solutions by fostering growth and innovation.
Recent Developments
• In May 2024, SOPHiA GENETICS launched new whole genome sequencing capabilities. • In October 2023, Complete Genomics demonstrated technical and commercial momentum in the sequencing market through new customers, partnerships, and collaborations within one year of launching in the U.S. • In January 2024, Ultima Genomics announced the end of early access and the upcoming launch of UG 100. • In August 2023, PacBio and GeneDx launched a research collaboration with the University of Washington to study long-read whole genome sequencing for increased diagnostic yield in neonatal care. • In February 2024, Veracyte completed the acquisition of C2i Genomics.
Key Players in the U.S. Genomics Market Illumina Inc. Thermo Fisher Scientific Inc. Agilent Technologies Luminex Corporation Myriad Genetics Inc. BGI Genomics Co. Ltd. Bio Rad Laboratories Inc. Caris Life Sciences Danaher Corp. Eurofins Scientific SE
Table of content 1. Introduction 1.1. Report Description 1.2. Research Methodology 1.2.1. Data Mining 1.2.2. Market Modeling and Forecasting 1.2.3. Data Validation 1.2.4. Industry Analysis
4. U.S. Genomics Market by Application & Technology Outlook Type 4.1. Introduction 4.2. U.S. Genomics Market Size and Growth Rate by Application & Technology Outlook Type (2021-2030) 4.3. Functional Genomics 4.3.1. Functional Genomics Market Size and Growth Rate (2022 - 2030) 4.4. Transfection 4.4.1. Transfection Market Size and Growth Rate (2022 - 2030) 4.5. Real-Time PCR 4.5.1. Real-Time PCR Market Size and Growth Rate (2021-2030) 4.6. PTFE Functional Genomics 4.6.1. PTFE Functional Genomics Market Size and Growth Rate (2021-2030) 4.7. Nylon Functional Genomics 4.7.1. Nylon Functional Genomics Market Size and Growth Rate (2021-2030) 4.8. RNA Interference 4.8.1. RNA Interference Market Size and Growth Rate (2022 - 2030) 4.9. Mutational Analysis 4.9.1. Mutational Analysis Market Size and Growth Rate (2022 - 2030) 4.10. SNP Analysis 4.10.1. SNP Analysis Market Size and Growth Rate (2021-2030) 4.11. Microarray Analysis 4.11.1. Microarray Analysis Market Size and Growth Rate (2021-2030) 4.12. Epigenomics 4.12.1. Epigenomics Market Size and Growth Rate (2021-2030) 4.13. Bisulfite Sequencing 4.13.1. Bisulfite Sequencing Market Size and Growth Rate (2021-2030) 4.14. Chromatin Immunoprecipitation (ChIP & ChIP-Seq) 4.14.1. Chromatin Immunoprecipitation (ChIP & ChIP-Seq) Market Size and Growth Rate (2021-2030) 4.15. Methylated DNA Immunoprecipitation (MeDIP) 4.15.1. Methylated DNA Immunoprecipitation (MeDIP) Market Size and Growth Rate (2021-2030) 4.16. High-Resolution Melt (HRM) 4.16.1. High-Resolution Melt (HRM) Market Size and Growth Rate (2021-2030) 4.17. Chromatin Accessibility Assays 4.17.1. Chromatin Accessibility Assays Market Size and Growth Rate (2021-2030) 4.17. Proteomics Tools (2-D PAGE; yeast 2-hybrid studies) 4.17.1. Proteomics Tools (2-D PAGE; yeast 2-hybrid studies) Market Size and Growth Rate (2021-2030) 4.18. Pathway Analysis 4.18.1. Pathway Analysis Market Size and Growth Rate (2021-2030) 4.19. Bead-Based Analysis 4.19.1. Bead-Based Analysis Market Size and Growth Rate (2021-2030) 4.20. Biomarker Discovery 4.20.1. Biomarker Discovery Market Size and Growth Rate (2021-2030) 4.21. Mass Spectrometry 4.21.1. Mass Spectrometry Market Size and Growth Rate (2021-2030) 4.22. Statistical Analysis 4.22.1. Statistical Analysis Statistical Analysis Market Size and Growth Rate (2021-2030) 4.23. Bioinformatics 4.23.1. Bioinformatics Market Size and Growth Rate (2021-2030) 4.24. DNA Sequencing 4.24.1. DNA Sequencing Market Size and Growth Rate (2021-2030) 4.25. Others 4.25.1. Others Market Size and Growth Rate (2021-2030)
5. U.S. Genomics Market by Deliverables Outlook 5.1. Introduction 5.2. U.S. Genomics Market Size and Growth Rate by Deliverables Outlook (2021-2030) 5.3. Products 5.3.1. Products Market Size and Growth Rate (2021-2030) 5.4. Instruments/Systems/Software 5.4.1. Instruments/Systems/Software Market Size and Growth Rate (2021-2030) 5.5. Consumables & Reagents 5.5.1. Consumables & Reagents Market Size and Growth Rate (2021-2030) 5.6. Services 5.6.1. Services Market Size and Growth Rate (2021-2030) 5.8. NGS-based Services 5.8.1. NGS-based Services Market Size and Growth Rate (2021-2030) 5.7. Core Genomics Services 5.7.1. Core Genomics Services Size and Growth Rate (2021-2030) 5.9. Biomarker Translation Services 5.9.1. Biomarker Translation Services Size and Growth Rate (2021-2030) 5.10. Computational Services 5.10.1. Computational Services Size and Growth Rate (2021-2030) 5.11. Others 5.11.1. Others Size and Growth Rate (2021-2030)
6. U.S. Genomics Market by End-use Outlook 6.1. Introduction 6.2. U.S. Genomics Market Size and Growth Rate by End-use Outlook (2021-2030) 6.3. Clinical Research 6.3.1. Clinical Research Market Size and Growth Rate (2021-2030) 6.4. Academic & Government Institutes 6.4.1. Academic & Government Institutes Market Size and Growth Rate (2021-2030) 6.5. Pharmaceutical & Biotechnology Companies 6.5.1. Pharmaceutical & Biotechnology Companies Size and Growth Rate (2021-2030) 6.6. Other End-users 6.6.1. Other End-usersSize and Growth Rate (2021-2030)
7. Company Profiles 7.1. Graver Technologies, LLC 7.1.1. Business Overview 7.1.2. Application & Technology Outlook Portfolio 7.1.3. Strategic Developments 7.1.4. Financial Overview
7.2. Eaton Corporation Plc, Inc. 7.2.1. Business Overview 7.2.2. Application & Technology Outlook Portfolio 7.2.3. Strategic Developments 7.2.4. Financial Overview
7.3. Merck & Co..Inc 7.3.1. Business Overview 7.3.2. Application & Technology Outlook Portfolio 7.3.3. Strategic Developments 7.3.4. Financial Overview
7.4. Parker-Hannifin Corporation 7.4.1. Business Overview 7.4.2. Application & Technology Outlook Portfolio 7.4.3. Strategic Developments 7.4.4. Financial Overview
7.5. Sartorius Stedim Biotech S.A 7.5.1. Business Overview 7.5.2. Application & Technology Outlook Portfolio 7.5.3. Strategic Developments 7.5.4. Financial Overview
7.6. 3M Company 7.6.1. Business Overview 7.6.2. Application & Technology Outlook Portfolio 7.6.3. Strategic Developments 7.6.4. Financial Overview
7.7. Amazon Filters Ltd 7.7.1. Business Overview 7.7.2. Application & Technology Outlook Portfolio 7.7.3. Strategic Developments 7.7.4. Financial Overview
7.8. Danaher Corporation (Pall Corporation) 7.8.1. Business Overview 7.8.2. Application & Technology Outlook Portfolio 7.8.3. Strategic Developments 7.8.4. Financial Overview
7.9. Eaton Corporation Plc. 7.9.1. Business Overview 7.9.2. Application & Technology Outlook Portfolio 7.9.3. Strategic Developments 7.9.4. Financial Overview
7.10. General Electric Company (GE Healthcare) 7.10.1. Business Overview 7.10.2. Application & Technology Outlook Portfolio 7.10.3. Strategic Developments 7.10.4. Financial Overview
8. List of Tables and Figures Table U.S. Genomics Market Size and Market Share by Application & Technology Outlook Type (2021-2023) Table U.S. Genomics Market Size and Market Share by Application & Technology Outlook Type (2023-2030) Figure Functional Genomics Market Size and Growth Rate (2021-2030) Figure Transfection Market Size and Growth Rate (2021-2030) Figure Real-Time PCR Market Size and Growth Rate (2021-2030) Figure RNA Interference Market Size and Growth Rate (2021-2030) Figure Mutational Analysis Market Size and Growth Rate (2021-2030) Figure SNP Analysis Market Size and Growth Rate (2021-2030) Figure Microarray Analysis Market Size and Growth Rate (2021-2030) Figure Epigenomics Market Size and Growth Rate (2021-2030) Figure Bisulfite Sequencing Market Size and Growth Rate (2021-2030) Figure Chromatin Immunoprecipitation (ChIP & ChIP-Seq) Market Size and Growth Rate (2021-2030) Figure Methylated DNA Immunoprecipitation (MeDIP) Market Size and Growth Rate (2021-2030) Figure High-Resolution Melt (HRM) Market Size and Growth Rate (2021-2030) Figure Chromatin Accessibility Assays Market Size and Growth Rate (2021-2030) Figure Pathway Analysis Market Size and Growth Rate (2021-2030) Figure Bead-Based Analysis Market Size and Growth Rate (2021-2030) Figure Proteomics Tools (2-D PAGE; yeast 2-hybrid studies) Market Size and Growth Rate (2021-2030) Figure Biomarker Discovery Market Size and Growth Rate (2021-2030) Figure Mass Spectrometry Market Size and Growth Rate (2021-2030) Figure Statistical Analysis Market Size and Growth Rate (2021-2030) Figure Bioinformatics Market Size and Growth Rate (2021-2030) Figure DNA Sequencing Market Size and Growth Rate (2021-2030) Figure Others Market Size and Growth Rate (2021-2030)
Table U.S. Genomics Market Size and Market Share by Deliverables Outlook (2021-2023) Table U.S. Genomics Market Size and Market Share by Deliverables Outlook (2023-2030) Figure Products Market Size and Growth Rate (2021-2030) Figure Instruments/Systems/Software Market Size and Growth Rate (2021-2030) Figure Consumables & Reagents Market Size and Growth Rate (2021-2030) Figure Services Market Size and Growth Rate (2021-2030) Figure NGS-based Services Market Size and Growth Rate (2021-2030) Figure Core Genomics Services Market Size and Growth Rate (2021-2030) Figure Biomarker Translation Services Market Size and Growth Rate (2021-2030) Figure Computational Services Market Size and Growth Rate (2021-2030) Figure Others Market Size and Growth Rate (2021-2030)
Table U.S. Genomics Market Size and Market Share by End-use Outlook (2021-2023) Table U.S. Genomics Market Size and Market Share by End-use Outlook (2023-2030) Figure Clinical Research Market Size and Growth Rate (2021-2030) Figure Academic & Government Institutes Market Size and Growth Rate (2021-2030) Figure Hospitals & Clinics Market Size and Growth Rate (2021-2030) Figure Pharmaceutical & Biotechnology Companies Market Size and Growth Rate (2021-2030) Figure Other End-users Market Size and Growth Rate (2021-2030)
Table U.S. Genomics Market by Regions (2021-2023) Table U.S. Genomics Market by Regions (2023-2030) Figure North America U.S. Genomics Market Size and Growth Rate (2021-2030) Table North America U.S. Genomics Market by Application & Technology Outlook Type (2021-2023) Table North America U.S. Genomics Market by Application & Technology Outlook Type (2023-2030) Table North America U.S. Genomics by Deliverables Outlook (2021-2023) Table North America U.S. Genomics by Deliverables Outlook (2023-2030) Table North America U.S. Genomics by Country (2021-2023) Table North America U.S. Genomics by Country (2023-2030) Figure United States U.S. Genomics Market Size and Growth Rate (2021-2030) Table United States U.S. Genomics Market by Application & Technology Outlook Type (2021-2023) Table United States U.S. Genomics Market by Application & Technology Outlook Type (2023-2030) Table United States U.S. Genomics by Deliverables Outlook (2021-2023) Table United States U.S. Genomics by Deliverables Outlook (2023-2030) Figure Canada U.S. Genomics Market Size and Growth Rate (2021-2030) Table Canada U.S. Genomics Market by Application & Technology Outlook Type (2021-2023) Table Canada U.S. Genomics Market by Application & Technology Outlook Type (2023-2030) Table Canada U.S. Genomics by Deliverables Outlook (2021-2023) Table Canada U.S. Genomics by Deliverables Outlook (2023-2030)
Table Olympus Corporation U.S. Genomics Financial Overview
Table Illumina Inc. U.S. Genomics Financial Overview Table Thermo Fisher Scientific, Inc U.S. Genomics Financial Overview Table Agilent Technologies U.S. Genomics Financial Overview Table Luminex Corporation U.S. Genomics Financial Overview Table Myriad Genetics Inc.U.S. Genomics Financial Overview Table BGI Genomics Co. Ltd U.S. Genomics Financial Overview Table Bio Rad Laboratories Inc.U.S. Genomics Financial Overview Table Caris Life Sciences U.S. Genomics Financial Overview Table Danaher Corp.U.S. Genomics Financial Overview Table Eurofins Scientific SE U.S. Genomics Financial Overview
Research Methodology
The process of market research at Ultra Market Research is an iterative in application and usually follows following path. Information from secondary used to build data models, then results from data models are validated from primary participants. Then cycle repeats where, according to inputs from primary participants, additional secondary research is done and new Information is again incorporated into data model. The process continues till desired level of Information is not generated
To calculate the market size, the report considers the revenue generated from the sales of Ultra Market Research providers. The revenue generated from the sales of Ultra Market Research has been calculated through primary and secondary research. The report also presents the key players operating in the Ultra Market Research market across the globe identified through secondary research and a corresponding detailed analysis of the top vendors in the market. The market size calculation also includes distribution channel segmentation determined using secondary sources and verified through primary sources.
Secondary Research
The secondary research source that are typically referred to include, but are not limited to:
Company websites, annual reports, financial reports, broker reports, investor presentations and SEC filings
Internal and external proprietary databases, relevant patent and regulatory databases
National government documents, statistical databases and market reports
News articles, press releases and web-casts specific to the companies operating in the market
The source for secondary research includes but is not limited to: Factiva, Hoovers and Statista
Inner Circle Represents – Stage of Research Process
Middle Circle Represents – Source of Information
Outer Circle Represents – Information Derived from that source
Primary Research We conduct primary interviews on an ongoing basis with industry participants and commentators in order to validate data and analysis. A typical research interview fulfills the following functions:
It provides first-hand Information on the market size, market trends, growth trends, competitive landscape, future outlook etc.
Helps in validating and strengthening the secondary research findings
Further develops the analysis team’s expertise and market understanding
Primary research involves E-mail interactions, telephonic interviews as well as face-to-face interviews for each market, category, segment and sub-segment across geographies
The participants who typically take part in such a process include, but are not limited to:
Industry participants: CEOs, VPs, marketing/ distribution channel managers, market intelligence managers and national sales managers
Purchasing managers, technical personnel, distributors and resellers
Outside experts: Investment bankers, valuation experts, research analysts specializing in specific markets
Key opinion leaders specializing in different areas corresponding to different industry distribution channels
Models Where no hard data is available, we use modeling and estimates in order to produce comprehensive data sets. A rigorous methodology is adopted in which the available hard data is cross referenced with the following data distribution channels to produce estimates:
Demographic data: Population split by segment
Macro-economic indicators: GDP, etc.
Industry indicators: Expenditure, distribution channel stage & infrastructure, sector growth and facilities.
Data is then cross checked by the expert panel.
2..1 Company Share Analysis Model
Company share analysis is used to derive the size of Global market. As well as study of revenues of companies for last three to five years also provide the base for forecasting the market size and its growth rate. This model is built in following steps: 2..2 Revenue Based Modeling
Revenue based models can be built in two ways – Top-Down or Bottom-Up irrespective of industry. Market size estimated from company share analysis acts as a validation point for bottom-up approach where as it acts as starting point for top-down approach.
2.1 Research Limitations Inflation is not a part of pricing in this report. Prices of U.S. Genomics and its derivatives vary in each region and hence similar revenue ratio does not follow for each individual region. The same price for each distribution channel has been taken into account while estimating and forecasting market revenue Globally. Regional average price has been considered while breaking down this market by application in each region. This report provides market size of U.S. Genomics Market for the past year and forecasts for the next six years. U.S. Genomics Market size is given in terms of revenue. Market revenue is defined in USD Million. Market numbers are given on the basis of different Over the Counter (OTC) Market categories. Market size and forecasts for each major application is provided in the context of Global market. The numbers provided in this report are derived on the basis of demand for U.S. Genomics from different application industries in different regions.
